Maryland Heights, Missouri — According to state and local development sources, Sentio BioSciences plans to invest $10,600,000.00 to expand in Maryland Heights. The company plans to occupy the new space at 218 A Millwell Dr in Maryland Heights, on or about March 1, 2026. According to the company website We are a CDMO focused on advanced pharmaceutical development, manufacturing and commercialization of Complex Pharmaceutical Molecules, High Potency molecules, and Toxic Substances in highly contained environment, using Advanced Manufacturing Techniques like Flow Chemistry, Continuous Manufacturing, and Batch Manufacturing where appropriate. We manufacture KSMs, APIs, Drug Products at pilot, clinical & commercial population scale. Our capabilities include completing all aspects needed for API DMF & Drug Product FDA registration. Our facility & systems are cGMP compliant & audited by the FDA every 2 years.

To learn more about Sentio BioSciences, visit http://www.sentiobiosciences.com/

Company Contact:
Karthik Raghavan, Chief Executive Officer
314-227-3700

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.